<DOC>
	<DOC>NCT02935335</DOC>
	<brief_summary>AME is a non-interventional, prospective, longitudinal and multicenter study. This study aims to measure the relationship between antimüllerian hormone serum level (AMH), as measured by a single fully automated assay (Elecsys®) and the initial dose of Menopur® Highly Purified-human Menopausal Gonadotrophin (HP-hMG) 600 IU/mL prescribed for infertile women undergoing their first In Vitro Fertilization (IVF)/Intra Cytoplasmic Sperm Injection (ICSI) cycle in the current practice.</brief_summary>
	<brief_title>A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>Women aged between [1842] years. Both ovaries present. Regular menstrual cycles presumed to be ovulatory. Primary or secondary infertility of any origin for more than 12 months. Patient with at least one result of antimüllerian hormone (AMH) measured by Elecsys® available before inclusion, and performed in the past 12 months before inclusion. Candidates eligible to a first IVF/ICSI cycle and for whom Menopur® HPhMG 600 IU/mL has been prescribed. Having received oral and written information on the study, without any objections for the use of his/her anonymized data, and having signed a written Informed Consent Form. Major uterine or ovarian morphological abnormalities or past ovarian surgery. Endometriosis stage III/IV. Polycystic ovarian syndrome. Major endocrine or metabolic abnormalities without treatment. Patient included in an interventional study assessing treatment for infertility.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>